News & Updates

Chewing xylitol gum daily was associated with a reduced risk of preterm birth, according to a trial conducted in Malawi and presented at SMFM 2022.

In the real-world treatment of Asian patients with type 2 diabetes mellitus (T2DM), the blood glucose-lowering benefit following oral antidiabetic drug (OAD) dose escalation is lesser than what has been reported in clinical trials, according to a study from Singapore.

Use of selective serotonin reuptake inhibitors (SSRIs) poses no risk of noncardioembolic ischaemic stroke and is even protective when compared with other antidepressants, according to a recent study.

The presence of appendicolith is tied to an almost twofold risk of requiring an appendectomy within 30 days in patients who initially received antibiotic therapy for acute uncomplicated appendicitis, according to an analysis of the CODA* study from the US.

Using the probiotic Escherichia coli Nissle 1917 (EcN) as add-on therapy for patients with mild-to-moderate ulcerative colitis (UC) helps induce disease remission and preserve quality of life (QoL) in these patients, according to studies presented at CCC 2022.

REL-1017 (esmethadone), a novel N-methyl-D-aspartate receptor channel blocker, demonstrates favourable safety, tolerability, and pharmacokinetic profiles and appears to have rapid and sustained antidepressant effects relative to placebo in major depressive disorder patients with inadequate responses to antidepressant treatments, according to a recent study.

In individuals with progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC), the VEGFR-2* inhibitor apatinib demonstrated significant clinical benefits in terms of progression-free survival (PFS) and overall survival (OS), with a manageable safety profile, findings from the phase III REALITY trial suggest.

The oral selective inhibitor of exportin-1 (XPO1) selinexor has therapeutic potential in recurrent glioblastoma, yielding favourable responses and clinically relevant 6-month progression-free survival (PFS) rate with manageable side effects requiring dose reductions, according to the results of a phase II trial.